1.            Have you changed your DLR personnel monitoring period (i.e. 
quarterly to 6 months, 6 months to annual)? We went from quarterly to every 6 
months on 1/1/2010.
2.            Did you experience a change in the number of individuals with 
dose less than 10 mrem and /or greater than 10 mrem? Greater.
3.            What DLR's are used at your site for personnel monitoring (i.e. 
TLD, OSL)?  Who is the processor (i.e. Harshaw, Landauer)? TLDs. We process our 
own.
4.            What is the lowest mrem you report annually? Basis? 10 mrem. LLD 
determination.
5.            What is your criterion for monitoring workers? (i.e. Are workers 
who never enter the RCA issued a DLR?). Yes, based on area TLD data.

From: Parlatore, Linda M:(GenCo-Nuc) [mailto:[email protected]]
Sent: Monday, February 27, 2017 10:58 AM
To: [email protected]
Cc: Ridge, Rose Marie A:(GenCo-Nuc)
Subject: [powernet] Benchmark Response Request Question #1 of 2



*** Exercise caution. This is an EXTERNAL email. DO NOT open attachments or 
click links from unknown senders or unexpected email. ***
TMI is performing a benchmark on external dosimetry. Question #1 (of 2)concerns 
DLR's (Dosimeter Legal Record - i.e. TLD, OSL).  Responses are appreciated.  If 
you would prefer to call instead, I can be reached at 717-948-8075.

  1.  Have you changed your DLR personnel monitoring period (i.e. quarterly to 
6 months, 6 months to annual)?
  2.  Did you experience a change in the number of individuals with dose less 
than 10 mrem and /or greater than 10 mrem?
  3.  What DLR's are used at your site for personnel monitoring (i.e. TLD, 
OSL)?  Who is the processor (i.e. Harshaw, Landauer)?
  4.  What is the lowest mrem you report annually? Basis?
  5.  What is your criterion for monitoring workers? (i.e. Are workers who 
never enter the RCA issued a DLR?)


Linda M Parlatore CHP NRRPT
Three Mile Island
2625 River Road
Middletown, PA 17057
717.948.8075
717.948.8502 (fax)



This Email message and any attachment may contain information that is 
proprietary, legally privileged, confidential and/or subject to copyright 
belonging to Exelon Corporation or its affiliates ("Exelon"). This Email is 
intended solely for the use of the person(s) to which it is addressed. If you 
are not an intended recipient, or the employee or agent responsible for 
delivery of this Email to the intended recipient(s), you are hereby notified 
that any dissemination, distribution or copying of this Email is strictly 
prohibited. If you have received this message in error, please immediately 
notify the sender and permanently delete this Email and any copies. Exelon 
policies expressly prohibit employees from making defamatory or offensive 
statements and infringing any copyright or any other legal right by Email 
communication. Exelon will not accept any liability in respect of such 
communications. -EXCIP

Reply via email to